Clinical trials: Genomic Instability
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
High Grade Serous Ovarian Cancer, Cervical Cancer Screening
Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer
High-grade serous ovarian carcinoma (HGSOC) is the deadliest gynaecological tumour. The 5-year overall survival rate for advanced-stage disease is less than 30 per cent, due to diagnosis at an advanced stage.
- Conditions
- High Grade Serous Ovarian Cancer, Cervical Cancer Screening, Whole Genome Sequencing, Genomic Instability
- Trial name
- SHALLOW ROUTE (NCT07821879)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Claudius Regaud
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability
- Trial name
- NCT02966587
- Testing
- Durvalumab, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Washington
Bladder Cancer, Genomic Instability
Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.
- Trial name
- SELECT (NCT06294054)
- Testing
- neoadjuvant chemotherapy with cisplatine
- Where
- 7 sites in France
- Volunteers
- 707 people
- Sponsor
- University Hospital, Rouen
Chromosomal Instability, Low Grade Dysplasia Oral Cavity
Diagnostics for the Treatment of Progressive Mucosal Lesions of the Oral Cavity: a Prospective Study
Despite improvements in therapy, head and neck carcinomas still have a poor prognosis with a 5-year survival of ~ 50%. Malignancies of the head and neck area are (almost) always preceded by precursor lesions.
- Conditions
- Chromosomal Instability, Low Grade Dysplasia Oral Cavity, Loss of Heterozygostiy, Fluorescence In Situ Hybridization
- Trial name
- NCT02238574
- Testing
- surgery, follow up
- Where
- Netherlands
- Sponsor
- Maastricht University Medical Center
Cytogenetic Abnormality, Radiation Exposure
Genomic Instability in Vascular Surgeons
The past two decades have witnessed the development and growth of the endovascular techniques, however, this new technology is not exempt from risks, since its use requires an ionizing radiation exposure to both patients and…
- Trial name
- IRADIENT (NCT04363190)
- Testing
- Cytogenetic analysis
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Solid Tumor, Microsatellite Instability
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
The purpose of this study is to determine the safety, tolerability, and recommended dose schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.
- Conditions
- Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency, Cancer of Unknown Primary Site
- Trial name
- NCT03053466
- Testing
- APL-501
- Where
- 5 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Apollomics (Australia) Pty. Ltd.
Epithelial Ovarian Cancer, Nucleotide Variant
Genetic Mutation in Epithelial Ovarian Cancer
Little is known about the characteristics of genetic mutation in a large multi-gene panel in epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than…
- Conditions
- Epithelial Ovarian Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation
- Trial name
- NCT04191252
- Testing
- A multi-gene panel testing
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Lei Li
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
The purpose of this study is to determine if dMMR and/or POLE exonuclease domain mutant stage III colon cancer patients gain clinical benefit (i.e.
- Conditions
- POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer
- Trial name
- POLEM (NCT03827044)
- Testing
- Avelumab
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Cancer
Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan
We will explore the genetic (including APC, k-ras, p53, MSI, etc.) and environmental (including family history, life style, diet, nutritional status, DM, serum IGF-I, IGFBP-3, etc.) risk factors of colorectal tumorigenesis.
- Trial name
- NCT00172757
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Anesthesia; Adverse Effect
Does Sevoflurane Cause Genomic Damage
This study aims to find out if sevoflurane causes any cell damage to patients undergoing general anaesthesia. In case of any damage, the reversibility of the damage is also assessed.
- Trial name
- NCT03109119
- Testing
- Sevoflurane, Propofol
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Jubilee Mission Medical College and Research Institute
Microsatellite Instability, Colorectal Cancer Stage IV
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
This pilot trial studies how well serial liquid biopsies work in detecting microsatellite instability in participants with stage IV colorectal cancer.
- Trial name
- NCT03594448
- Testing
- Specimen Collection, Serial Liquid Biopsy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Colorectal Cancer
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)
- Trial name
- NCT06428487
- Testing
- Prolgolimab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Longitudinal, Genomic Stability
Epidemiology and Overtime Genomic Evolution of Klebsiella Pneumoniae and Enterobacter Cloacae Complex (ECC) in Stools of ICU's Patients
Infections are one of the major threats for inpatients, even more for patients hospitalized in intensive care units (ICUs). They are responsible for an important increase of morbidity and mortality rates as well as a burst of…
- Conditions
- Longitudinal, Genomic Stability, Klebsiella Infections, Enterobacter Cloacae Infection
- Trial name
- NormandyKlebs (NCT07744321)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Caen
Bladder Cancer
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor…
- Trial name
- NCT06153849
- Testing
- urine sample collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Endometrial Cancer
Non-Invasive Diagnosis of Endometrial Cancer
The study aims to determine whether next generation sequencing and microsatellite analysis of cervical cytology is sensitive for the detection of endometrial carcinoma.
- Trial name
- NIECE (NCT05737797)
- Testing
- cervical cytology during surgery.
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
Safety of Ginkgo Biloba Leaf Extract
Primary objective: The primary objective of this study is to assess the effect of Ginkgo biloba L. leaf extract (IDN 5933) in comparison to placebo in human subjects treated at therapeutic doses for 6 months on the level of DNA…
- Trial name
- GiBiEx (NCT03004508)
- Testing
- Gingko Biloba Extract
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- IRCCS San Raffaele